{"disease":{"id":"22q11-2-syndrome","name":"22q11 2 syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03836300","title":"Parent and Infant Inter(X)Action Intervention (PIXI)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT07493096","title":"Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Healing Hope International","has_results":false},{"nct_id":"NCT04639388","title":"Understanding of Psychotic Disorders in Children With 22q11.2DS","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Hôpital le Vinatier","has_results":false},{"nct_id":"NCT04647500","title":"Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"University of Geneva, Switzerland","has_results":false},{"nct_id":"NCT04373226","title":"Arithmetic Abilities in Children With 22q11.2DS","phase":"NA","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Hôpital le Vinatier","has_results":false},{"nct_id":"NCT05149898","title":"Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Harmony Biosciences Management, Inc.","has_results":true},{"nct_id":"NCT04639960","title":"Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome","phase":"NA","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"University of Geneva, Switzerland","has_results":false},{"nct_id":"NCT03284060","title":"Social Cognition Training and Cognitive Remediation","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Hôpital le Vinatier","has_results":false},{"nct_id":"NCT02895906","title":"Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Aevi Genomic Medicine, LLC, a Cerecor company","has_results":false},{"nct_id":"NCT00105274","title":"Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study","phase":"","overall_status":"COMPLETED","enrollment_count":null,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}